Go Pro
→ Why Boston Ships In Natural Gas It Already Has at Home (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biodesix, Inc. stock logo
BDSX
Biodesix
$29.80
+6.1%		$21.89
$5.26
▼
$30.08
$315.23M0.56600,777 shs86,470 shs
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$12.02
0.0%		$10.30
$7.29
▼
$12.97
$242.49M1.42166,645 shs18,014 shs
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
$10.19
-1.2%		$10.69
$1.52
▼
$16.89
$73.94M1.63534,081 shs5,150 shs
Exagen Inc. stock logo
XGN
Exagen
$7.51
-1.2%		$5.31
$2.59
▼
$12.23
$181.99M2.05407,594 shs49,928 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biodesix, Inc. stock logo
BDSX
Biodesix
+10.59%+25.69%+27.64%+89.60%+186.82%
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
+0.59%-1.72%+31.80%+29.95%+21.78%
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
+2.79%-4.27%+7.17%-35.28%+38.58%
Exagen Inc. stock logo
XGN
Exagen
-0.65%+15.33%+62.39%+51.70%-22.84%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biodesix, Inc. stock logo
BDSX
Biodesix
$29.80
+6.1%		$21.89
$5.26
▼
$30.08
$315.23M0.56600,777 shs86,470 shs
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$12.02
0.0%		$10.30
$7.29
▼
$12.97
$242.49M1.42166,645 shs18,014 shs
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
$10.19
-1.2%		$10.69
$1.52
▼
$16.89
$73.94M1.63534,081 shs5,150 shs
Exagen Inc. stock logo
XGN
Exagen
$7.51
-1.2%		$5.31
$2.59
▼
$12.23
$181.99M2.05407,594 shs49,928 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biodesix, Inc. stock logo
BDSX
Biodesix
+10.59%+25.69%+27.64%+89.60%+186.82%
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
+0.59%-1.72%+31.80%+29.95%+21.78%
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
+2.79%-4.27%+7.17%-35.28%+38.58%
Exagen Inc. stock logo
XGN
Exagen
-0.65%+15.33%+62.39%+51.70%-22.84%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biodesix, Inc. stock logo
BDSX
Biodesix
2.80
Moderate Buy$31.335.16% Upside
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
2.75
Moderate Buy$16.6738.72% Upside
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
2.00
Hold$17.0066.91% Upside
Exagen Inc. stock logo
XGN
Exagen
2.89
Moderate Buy$9.6328.16% Upside

Current Analyst Ratings Breakdown

Latest PIII, BDSX, INFU, and XGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/11/2026
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
Lake Street Capital logo
Lake Street Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$23.00
8/10/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$27.00 ➝ $35.00
8/7/2026
Exagen Inc. stock logo
XGN
Exagen
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/6/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$26.00 ➝ $27.00
8/5/2026
Exagen Inc. stock logo
XGN
Exagen
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$8.00 ➝ $10.00
8/5/2026
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$12.00 ➝ $20.00
8/5/2026
Exagen Inc. stock logo
XGN
Exagen
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$8.00 ➝ $12.00
8/5/2026
Exagen Inc. stock logo
XGN
Exagen
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$8.00 ➝ $9.00
6/24/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$32.00
6/24/2026
Exagen Inc. stock logo
XGN
Exagen
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$8.00
(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biodesix, Inc. stock logo
BDSX
Biodesix
$88.50M3.55N/AN/A$0.87 per share34.25
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$143.34M1.69$0.94 per share12.79$2.47 per share4.86
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
$1.46B0.05N/AN/A($12.57) per share-0.81
Exagen Inc. stock logo
XGN
Exagen
$66.57M2.73N/AN/A$0.50 per share15.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biodesix, Inc. stock logo
BDSX
Biodesix
-$35.26M-$3.17N/AN/AN/A-26.97%-788.19%-30.33%11/2/2026 (Estimated)
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$870K$0.41200.2838.76N/A1.12%2.78%1.41%N/A
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
-$147.95M-$33.00N/AN/AN/A-6.55%N/A-16.40%11/12/2026 (Estimated)
Exagen Inc. stock logo
XGN
Exagen
-$19.95M-$0.81N/AN/AN/A-26.61%-104.46%-28.93%11/3/2026 (Estimated)

Latest PIII, BDSX, INFU, and XGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
-$1.89-$0.63+$1.26-$0.63$377.80 million$386.38 million
8/5/2026Q2 2026
Biodesix, Inc. stock logo
BDSX
Biodesix
-$0.9018-$0.71+$0.1918-$0.71$26.03 million$26.86 million
8/4/2026Q2 2026
Exagen Inc. stock logo
XGN
Exagen
-$0.1914-$0.13+$0.0614-$0.13$17.80 million$19.94 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biodesix, Inc. stock logo
BDSX
Biodesix
N/AN/AN/AN/AN/A
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
N/AN/AN/AN/AN/A
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
N/AN/AN/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biodesix, Inc. stock logo
BDSX
Biodesix
5.12
2.85
2.85
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
0.50
1.98
1.59
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
N/A
0.46
0.46
Exagen Inc. stock logo
XGN
Exagen
1.96
3.18
3.18

Institutional Ownership

CompanyInstitutional Ownership
Biodesix, Inc. stock logo
BDSX
Biodesix
20.96%
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
71.13%
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
7.75%
Exagen Inc. stock logo
XGN
Exagen
75.25%

Insider Ownership

CompanyInsider Ownership
Biodesix, Inc. stock logo
BDSX
Biodesix
23.20%
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
10.80%
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
10.86%
Exagen Inc. stock logo
XGN
Exagen
10.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biodesix, Inc. stock logo
BDSX
Biodesix
22010.55 million8.10 millionNo Data
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
41020.18 million19.10 millionOptionable
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
5007.26 million6.47 millionNot Optionable
Exagen Inc. stock logo
XGN
Exagen
22024.23 million21.71 millionOptionable

Recent News About These Companies

GSA Capital Partners LLP Makes New Investment in Exagen Inc. $XGN
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-gsa-capital-partners-llp-makes-new-investment-in-exagen-inc-xgn-2026-08-18/
Flputnam Investment Management Co. Takes $1.34 Million Position in Exagen Inc. $XGN
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-flputnam-investment-management-co-takes-134-million-position-in-exagen-inc-xgn-2026-08-18/
Exagen (XGN) Q2 2026 Earnings Call Transcript
August 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/exagen-xgn-q2-2026-earnings-173108751.html
BTIG Research Forecasts Strong Price Appreciation for Exagen (NASDAQ:XGN) Stock
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/btig-research-forecasts-strong-price-appreciation-for-exagen-nasdaqxgn-stock-2026-08-05/
Exagen: The Path To Profitability Just Became More Credible
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4930529-exagen-the-path-to-profitability-just-became-more-credible
Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Revenue and Path to Profitability
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/exagen-inc-xgn-q2-2026-210322275.html
Exagen Q2 Earnings Call Highlights
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/exagen-q2-earnings-call-highlights-2026-08-04/
Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript
August 4, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4930137-exagen-inc-xgn-q2-2026-earnings-call-transcript
Exagen Inc. Reports Second Quarter 2026 Financial Results
August 4, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/exagen-inc-reports-second-quarter-2026-financial-results-1036405720
Exagen reports record second-quarter 2026 revenue and raises full-year guidance
August 4, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/exagen-reports-record-second-quarter-2026-revenue-and-raises-full-year-guidance/ar-AA29opCC
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
August 4, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2967397/exagen-inc-xgn-reports-q2-loss-beats-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2967397
Exagen (NASDAQ:XGN) Announces Quarterly Earnings Results
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/exagen-nasdaqxgn-announces-quarterly-earnings-results-2026-08-04/
Exagen Reports Record Second-Quarter Revenue and Narrows Losses, Raises Full-Year 2026 Guidance
August 4, 2026  |  quiverquant.comQ
Exagen reports record Q2 revenue of $19.9 million
August 4, 2026  |  quiverquant.comQ
Exagen Inc. (NASDAQ:XGN) Given Consensus Recommendation of "Moderate Buy" by Brokerages
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/exagen-inc-nasdaqxgn-given-consensus-recommendation-of-moderate-buy-by-brokerages-2026-08-02/
Exagen (XGN) Projected to Release Earnings on Tuesday
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/exagen-xgn-projected-to-release-earnings-on-tuesday-2026-07-28/
Exagen Inc. to Participate in Upcoming Investor Conference
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334312/32920/en/exagen-inc-to-participate-in-upcoming-investor-conference.html
Exagen: A Small Diagnostics Company Approaching An Inflection Point
July 23, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4924495-exagen-stock-small-diagnostics-company-approaching-inflection-point
Exagen to Announce Second Quarter Financial Results on August 4, 2026
July 21, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/exagen-to-announce-second-quarter-financial-results-on-august-4-2026-1036345946
Exagen Shareholders Approve Directors, Auditor and Pay Package
June 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/exagen-shareholders-approve-directors-auditor-and-pay-package?utm_source=marketbeat.com&utm_medium=referral
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
June 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/01/3304433/32920/en/exagen-announces-publication-of-systematic-review-confirming-robust-real-world-performance-of-avise-lupus.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biodesix stock logo

Biodesix NASDAQ:BDSX

$29.80 +1.72 (+6.11%)
As of 11:39 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

InfuSystem stock logo

InfuSystem NYSE:INFU

$12.02 -0.01 (-0.04%)
As of 11:39 AM Eastern
This is a fair market value price provided by Massive. Learn more.

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

P3 Health Partners stock logo

P3 Health Partners NASDAQ:PIII

$10.18 -0.13 (-1.21%)
As of 11:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.

Exagen stock logo

Exagen NASDAQ:XGN

$7.51 -0.09 (-1.18%)
As of 11:37 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas